AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M) ($M)
Form 8-K Non-GAAP Reconciliations
Latest, FY2025
6,495
Period ended Dec 31, 2025
Change on a year earlier
+72.2%
3,771 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,495 | +72.2% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 3,771 | -26.5% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 5,128 | +85.7% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 2,761 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Breakdown
What makes up specified item: change in fair value of contingent consideration — pre-tax ($m)
Cite this data
StockData. (2026). AbbVie Specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap_spec_cc_pretax
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.